Daily Medication Pearl: Aducanumab-avwa (Aduhelm) for Alzheimer Disease

Aducanumab-avwa is a human, immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta.

Medication Pearl of the Day: Aducanumab-avwa (Aduhelm)

Indication: Aducanumab-avwa is an amyloid beta-directed antibody indicated for the treatment of Alzheimer disease.

Insight:

  • Dosing: The recommended maintenance dosage is 10 mg/kg administered as an intravenous infusion over approximately 1 hour every 4 weeks.
  • Dosage form: 170 mg/1.7 mL (100 mg/mL) solution in a single-dose vial and 300 mg/3 mL (100 mg/mL) solution in a single-dose vial.
  • Adverse events (AEs): Most common AEs (at least 10% and higher incidence compared to placebo): ARIA-Edema, headache, ARIA-H microhemorrhage, ARIA-H superficial siderosis, and fall.
  • Mechanism of action: Aducanumab-avwa is a human, immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta.
  • Manufacturer: Biogen

Sources: